Alzheimer's Disease
Conditions
Interventions
Vascular cognitive impairment and other cognitive disorders:None
Alzheimer's dementia:None
Subjective cognitive decline:None
Health control:None
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People with cognitive impairment: 1. Outpatients and inpatients of the Department of Cognitive Disorders in Beijing Tiantan Hospital, Capital Medical University and the Second Affiliated Hospital of Xuzhou Medical College from January 2019 to December 2025; 2. age =18 years old; 3. The diagnosis of cognitive impairment meets the corresponding clinical diagnostic criteria, as follows: AD patients were required to meet the 2011 National Institute on Aging and Alzheimer's Disease Association (NIA-AA) diagnostic criteria of "probable AD dementia" or meet the 2018 NIA-AA diagnostic framework of "ATN"; Patients with mild cognitive impairment (MCI) were required to meet the 2004 Petersen amnestic MCI criteria. Patients with Subjective Cognitive Decline (SCD) were eligible for the 2014 Subjective Cognitive Decline Initiative. The concept of SCD proposed by SCD-I and in line with the characteristics of SCD added by SCD-I in 2020; Patients with vascular cognitive impairment (VCI) were required to meet the diagnostic criteria of vascular cognitive impairment issued by the Vascular Behavior and Cognitive Impairment Society International (Vas-Cog) in 2014. Patients with frontotemporal lobar degeneration (FTD) were required to meet the diagnostic criteria of "probable bvFTD" revised by Rascovsky et al. 2011 and "nfvPPA and svPPA supported by imaging" revised by Gorno-Tempini et al. 2011. Dementia with Lewy bodies (DLB) was defined as "probable DLB" by the International DLB Consortium in 2017. Patients with cognitive impairment caused by other causes, such as CSFIR gene mutations and autoimmune encephalitis 4. understand the instructions and cooperate with the improvement of serological test, scale evaluation and brain magnetic resonance examination; 5. Patients or their immediate family members agreed and signed the informed consent. Normal control population: 1. Age =18 years old; 2. Subjective and objective assessment found no evidence of cognitive decline; 3. can understand the instructions and cooperate with the serological test, scale evaluation and brain magnetic resonance examination; 4. Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Serological test can not be improved due to various reasons; 2. Various reasons can not cooperate with the improvement of the scale, such as strict attention to hearing disorders, serious mental behavior abnormalities; 3. There are contraindications in craniocerebral MRI, such as claustrophobia after plate implantation; Or because of restlessness, unable to cooperate with the imaging examinations; 4. There have been other central nervous system injuries leading to cognitive decline, such as severe craniocerebral trauma, primary central nervous system tumors, etc.; 5. Patients with serious diseases, life expectancy is very short, such as metastasized end-stage cachexia; 6. The patient and his immediate family do not agree to sign the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini-mental state examination;Montreal cognitive assessment;The Hopkins Vocabulary Learning Test;Cognitive-12 scale;Activity of daily living;Subjective cognitive decline questionnaire-9;Neuropsychiatric inventory;Hamilton depression scale;Hamilton anxiety scal;Pittsburgh Sleep Quality Index Scale;Mini-nutritional assessment;Hachinski ischemic scale;Caregiver Burden Inventory;Gene;AD related pathological marker;Intestinal flora metagenome;Urine composition;Magnetic resonance image data; | — |
Countries
China
Contacts
Public ContactJun xu
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed